Objective-Calcific aortic stenosis, characterized by excessive fibrosis and deposition of bone-like calcified tissue, affects roughly 2% to 3% of the U.S. population over the age of 65. Recent studies have suggested that statins have a positive effect on the progression of aoritic stenosis, likely because of their ability to affect the resident cell population, known as valvular interstitial cells (VICs). VICs are fibroblastic cells that can differentiate to form activated myofibroblasts, displaying increased alpha smooth muscle actin (␣SMA) expression, contractility, and collagen production. Methods and Results-In culture, VICs spontaneously form multicellular aggregates that subsequently develop into calcified nodules, providing an in vitro model for aortic stenosis. Using real-time microscopic tracking, we observed that confluent VIC monolayers spontaneously contract into rounded nodules, suggesting that myofibroblastic contractility is a critical step in the process of nodule formation. Overexpression of ␣SMA increased VIC calcific nodule formation and contractility, whereas knockdown of ␣SMA with siRNAs reduced these phenotypes, suggesting that the expression and contractile properties of ␣SMA are essential to the formation of nodules. Statin treatment of VICs reduced ␣SMA expression, inhibited contractility, and decreased nodule formation. When statins were used to treat preformed nodules, no decrease in the number of calcified nodules was observed, suggesting that statins may play more of a preventative role in aortic stenosis than a cure. Conclusions-Our studies provide evidence of a causal relationship between VIC myofibroblastic activity and initial VIC calcific nodule formation. Furthermore, we demonstrate that pravastatin inhibition of calcific nodule formation is related to inhibition of myofibroblastic activity.
V alvular stenosis is the leading cause of aortic heart valve failure in the United States, a disease that affects roughly 2% to 3% of the population over the age of 65. 1 It has long been thought that aortic stenosis is a degenerative process resulting from passive accumulation of calcium on the aortic valve cusps; however, recent evidence indicates that valvular disease is cell-mediated. 2 Valvular interstitial cells (VICs) are the main cell population of the four heart valves and play a critical role in regulating tissue homeostasis. In cases of aortic valve disease, chronic stresses are thought to result in prolonged activation of VICs, which differentiate to become myofibroblasts that express ␣-smooth muscle actin (␣SMA) as well as osteoblastic markers (osteocalcin and bone sialoprotein). [3] [4] [5] Over time, chronic activation of VICs likely leads to increased fibrosis of the valve leaflets and the formation of bone-like calcified nodules. These effects have catastrophic effects on the mechanical flexibility of the leaflets and compromise valve function.
Retrospective clinical studies have indicated that patients who are treated with statins for other heart-related issues have a 50% lower incidence of heart valve disease. 6 -9 This observation has resulted in renewed interest in the effects of statin treatment and the roles that statins play in cell function. Statins, a class of drugs that inhibit HMG-CoA reductase, have long been known for their cholesterol-lowering abilities but are beginning to demonstrate additional beneficial effects including atherosclerotic plaque stabilization, 10 enhancement of endothelial cell function, 11 and manipulation of cytokine production. 12 In the case of valvular stenosis, results have been mixed. Although there is agreement that statins can positively impact patients with valvular stenosis, questions remain as to whether statins reverse calcific phenotypes or solely prevent their progression. Regression of valvular stenosis has been reported in retrospective studies where patients who had been treated with statins had lower levels of valvular stenosis than patients not treated with statins. 6 -9,13 These studies, however, were limited by their nonrandomized, retrospective nature. Prospective clinical studies, on the other hand, have shown little to no effect of statin treatment on slowing or reversing stenotic progression. 14 -16 Clearly, further investigation into statin-mediated valvular disease prevention or regression is required to elucidate these paradoxical clinical results.
In the work presented here, we sought to identify the mechanism of statin action in valvular cells by uncovering the cellular events that lead to calcific nodule formation. Using an in vitro model in which porcine VICs were activated with transforming growth factor-beta1 (TGF-␤1) to form calcific nodules in culture, we observed that nodule formation occurs as a result of contractile events that are mediated by increased expression of ␣SMA. TGF-␤1 is a profibrotic growth factor that has been implicated in the development of VIC calcification in vitro and the progression of valvular stenosis in vivo. 17, 18 Additionally, TGF-␤1 has been shown to increase VIC ␣SMA expression and contractility when added to cultures. 19 In valvular stenosis, increased levels of TGF-␤1 have been hypothesized to lead to enhanced resident myofibroblast activity resulting in valvular sclerosis and subsequent stenosis. 17 In these studies TGF-␤1 was used to generate enhanced VIC calcific nodule activity. By blocking ␣SMA expression via a Rho-mediated pathway, statins effectively reduced the contractile activity of VICs and prevented nodule formation. When VIC cultures were treated with statins after the onset of myofibroblast activation and nodule formation, no reversal of calcific nodule numbers was observed. Together, these data provide a mechanism by which statins can prevent the contractile events that initiate nodule formation and thus block the progression of valvular stenosis.
Methods

Cell Culture
VICs were isolated from porcine aortic valve leaflets by sequential collagenase digestion as previously described. 20 Cells were expanded in growth media (Medium 199, 15% fetal bovine serum [FBS], 2% penicillin/streptomycin [100 U/mL], 0.4% fungizone [0.5 g/mL]) and passaged by trypsin digestion. For the experiments described here, VICs from passages 2 or 3 were plated at confluence and cultured in low serum media (1% FBS supplemented). TGF-␤1 (R&D Systems) was added at 5 ng/mL and pravastatin (EMD Bioscience) at 100 mol/L. Pravastatin was chosen as a statin inhibitor because of its water-soluble nature, thus eliminating the presence of solvent carriers required by other statins.
Real-Time VIC Nodule Formation
Time lapse images of VIC nodule formation were captured over a 48-hour period using a Nikon TE 2000 PFS epi-fluorescent microscope equipped with a motorized stage and an environmental sample chamber. Images were collected and analyzed using MetaMorph software (Molecular Devices).
Calcific Nodule Formation Assay
VICs were seeded onto 24-well plates at a concentration of 75 000 cells/cm 2 . The cells were cultured for 4 days before fixing with 10% buffered formalin (Sigma). Fixed cultures were stained with Alizarin Red S dye (Electron Microscopy Science). This histology stain marks hydroxyapatite mineralized matrix orange-red in color. Positively stained nodules were then counted and normalized to culture area.
Collagen Gel Contraction Assay
VICs were encapsulated in fixed collagen gels (Inamed) in 24-well plates at a density of 500 000 cells/mL per manufacturer's instructions. Cell-gel constructs were cultured fixed to the plate for 4 days with the indicated supplements before being released. On release, images of cell-gel constructs were captured over a 24-hour period to follow gel contraction. Reduction in gel area was measured after 24 hours using ImageJ (NIH) and normalized to initial gel size before release.
Cell Transfections and Luciferase Assays
Transfection of VICs with siRNAs and plasmid DNAs was accomplished using the amaxa Nucleofector system. siRNA pools were obtained from Dharmacon and used at a concentration of 2 mol/L. The ␣SMA expression plasmid (pCMV-␣SMA) was purchased from Origene, and the ␣SMA-luciferase plasmid (p␣SMA-luc) was provided by the laboratory of Dr Leslie Leinwand (Department of Molecular, Cellular and Developmental Biology, University of Colorado, Boulder). 21 Plasmid transfections were performed with 5 g of plasmid DNA. Luciferase activity was measured using the Promega Bright-Glo Luciferase Assay System per manufacturer's instructions.
␣SMA Cell-Based Fluorometric Enzyme-Linked Immunosorbent Protein Expression Assay
Protein expression of ␣SMA was analyzed with a cell-based fluorometric enzyme-linked immunosorbent assay as previously described. 22 Briefly, VICs seeded onto 96-well plates for 48 hours were fixed with 10% buffered formalin, permeabilized with Tween-20, blocked with 3 wt% BSA, and incubated with mouse anti-␣SMA IgG (Abcam) antibody and mouse-antigoat HRP coupled IgG (Invitrogen). Samples were then incubated with a fluorescent HRP substrate, QunataBlu (Pierce), and detected on a fluorescent plate reader. Cells were rinsed and lysed with papainase (Worthington) and dsDNA quantified with Quanti-It PicoGreen dsDNA (Invitrogen) fluorescent assay per manufacturers' instructions for normalization. Concurrently, cells were immunostained with mouseantigoat alexa 488 coupled IgG (Invitrogen) to visualize and confirm staining.
Quantifiable Real-Time Polymerase Chain Reaction
Messanger RNA (mRNA) was isolated from treated VIC cultures using the SV total RNA isolation kit (Promega) according to manufacturer's instructions. After isolation, mRNA purity and amount was confirmed with a NanoDrop (Thermo Fisher) spectrophotometer before reverse transcription was performed using iScript cDNA synthesis kit (BioRad). Amplification of cDNA products was performed using an iCycler (BioRad) and previously reported primers 23 (Integrated DNA Technologies). Data were analyzed according to the Pfaffl method and normalized to GAPDH. 24
Statistical Analysis
All statistical analyses were performed using a standard Student t test for significance. Data were considered significant if PϽ0.05. Values reported represent data mean, and error bars indicate SEM. Unless otherwise noted experiments were performed in triplicate.
Results
Nodule Formation Is Initiated By Contractile Events In VIC Cultures
When plated at confluence and treated with TGF-␤1, VIC cultures form rounded cell aggregates, or nodules, that stain positive for calcium deposition. 17, 18 This process has been likened to the formation of calcific nodules in the heart, providing a means to study some of the basic underlying mechanisms that lead to valvular stenosis.
Although it is well-documented that VICs form calcific nodules in culture, it is not clear what events initiate this process. Increased cell proliferation, migration, and apoptosis have all been attributed to causing nodules to form in culture, but no consensus has been reached. 17, 18, 25 In an effort to better understand how nodules form, we performed real-time tracking microscopy on VIC cultures treated with TGF-␤1, allowing us to effectively observe nodules form. Starting as a confluent monolayer, the cells initially showed signs of migration in that some local cell movement was observed. Within 12 hours, however, groups of VICs appeared to pull together to create cell clusters ( Figure 1 ). Based on the short time period in which the cells went from a monolayer to a nodule, we concluded that contraction, and not cell migration, was likely driving the formation of the nodules. This effect is more clearly observed in time-lapse videos of the cultures (supplemental Videos I and II, available online at http:// atvb.ahajournals.org.) in which cells furthest from the center of the forming nodules appear to be torn away from the culture plate in unison, leaving bare patches where no cells remain.
␣SMA Is Necessary and Sufficient for VIC Calcific Nodule Formation
These data suggest that ␣SMA expression, a hallmark of myofibroblast activation, has a causal effect on nodule formation. Because ␣SMA is a central component of myofibroblast-associated stress fibers, we hypothesized that the increased expression of ␣SMA in these cells would cause an increase in cellular contraction and, hence, nodule formation. Previous studies have confirmed the link between ␣SMA and contractile activity in fibroblasts, 26, 27 however the role of contractility in calcific nodule formation has not been elucidated. To test this hypothesis, we transfected VICs with an ␣SMA overexpression plasmid (pCMV-␣SMA) to specifically increase the expression of only ␣SMA. Although the addition of TGF-␤1 also increases the expression of ␣SMA, it also upregulates many other genes in a complex signaling cascade. After ␣SMA overexpression, the effect of increased ␣SMA expression on cellular contraction and nodule formation was measured. In gel contraction assays, transfected VICs were embedded in 3-dimensional collagen matrices and cultured for 48 hours before being released from the plate surface. After release, gel diameter was measured at specific time points, providing an estimate of the total contractile force exerted by the encapsulated cells. As hypothesized, VICs transfected with the pCMV-␣SMA plasmid showed increased ␣SMA protein expression ( Figure 2A ) and in-creased contractility ( Figure 2B ). The levels of ␣SMA expression were further increased by treatment with TGF-␤1 ( Figure 2A ) with a corresponding increase in collagen gel contraction ( Figure 2B ). Increasing ␣SMA expression also led to increased numbers of calcific nodules in subsequent 2D experiments ( Figure 2C ).
Given the apparent effects of increasing ␣SMA expression on contractility and calcific nodule formation of VIC cultures, we hypothesized that the opposite would be seen if ␣SMA expression was specifically decreased. To test this hypothesis, siRNAs were used to knock down ␣SMA expression. As shown in Figure 3A , protein levels of ␣SMA were significantly reduced in VICs treated with ␣SMA-targeting siRNAs when compared to cells treated with nontargeting siRNA controls. As expected, collagen gels containing VICs treated with ␣SMA-siRNAs showed decreased contraction ( Figure  3B ). While the addition of TGF-␤1 effectively increased contractility when compared to untreated control samples, a comparison of ␣SMA expression levels and contractility showed a strong correlation. In addition, reduced ␣SMA expression resulted in significantly reduced calcific nodules ( Figure 3C ). Together, these data suggest that increased ␣SMA expression is both necessary and sufficient for contraction-initiated nodule formation in VIC cultures.
Pravastatin Inhibits Nodule Formation
Because of the heightened interest in statins for their possible role in abrogating valvular stenosis, we tested the ability of pravastatin to block nodule formation in VIC cultures. As shown in Figure 4A , pravastatin treatment significantly reduced the number of calcific nodules formed. Treatment of VICs with TGF-␤1 doubled the number of calcific nodules, an effect that was blocked when TGF-␤1 was codelivered with pravastatin. Nodule formation in VIC cultures treated with both TGF-␤1 and pravastatin showed similar nodule numbers as cultures treated with pravastatin alone.
To ensure that pravastatin-mediated effects on VIC activity was specific to HMG-CoA reductase inhibition and not a nonspecific effect of the treatment conditions, we supplemented our VIC cultures with activated mevalonate, the immediate downstream metabolic product of HMG-CoA reductase activity. As shown in supplemental Figure I , the addition of mevalonate to the cultures abrogated pravastatinmediated effects on VIC activity. Furthermore, analysis of the downstream signaling pathways involved in pravastatin ac- 
Pravastatin Represses ␣SMA Transcription
Because ␣SMA expression appears to play a central role in myofibroblast contraction and subsequent nodule formation, we hypothesized that pravastatin inhibits ␣SMA expression. As shown in Figure 4B , increasing pravastatin concentrations reduced ␣SMA protein levels in a dose-dependent manner. As expected, pravastatin also reduced VIC contractile activity in collagen gel assays ( Figure 4C ).
To investigate whether statins repress ␣SMA transcription, VICs were transfected with an ␣SMA-luciferase reporter (p␣SMA-luc) followed by treatment with TGF-␤1 or pravastatin. After 48 hours, the luciferase activity of VICs treated with statins was significantly reduced when compared to controls ( Figure 4D ), indicating that pravastatin acts to block ␣SMA expression at the transcriptional level. As would be expected, TGF-␤1 significantly increased luciferase activity, an effect that was abrogated by codelivery with pravastatin. Pravastatin treatment of VICs also reduced ␣SMA expression at the transcriptional level as shown by quantifiable real-time polymerase chain reaction analysis ( Figure 4E ). Furthermore, this effect appears to be mediated by Smad transcription factors as pravastatin treatment also caused a decrease in luciferase activity in VICs transfected with a pSmad-luc reporter plasmid (supplemental Figure IV) .
Pravastatin Does Not Reverse Calcific Nodule Phenotype
Although it is clear that statins are capable of inhibiting nodule formation, the ability of statins to cause a reversal of calcific nodules remains controversial. To test this, confluent VIC cultures were allowed to form nodules for 4 days before treatment with pravastatin. As shown in Figure 5 , pravastatin blocked an increase in calcific nodules but did not appear to reduce the number of calcified nodules that were observed. Interestingly, although the number of calcium positive nodules was unaffected by pravastatin treatment, the nodules that were present in these samples appeared to have a flattened profile even though they stained positive for calcium, likely because of a decrease in cellular contractility (supplemental Figure V) .
Discussion
In the work presented here, we identify the underlying mechanism of initial calcific nodule formation in VIC cultures and explore the signaling pathways involved in statinmediated inhibition of this phenotype. By artificially altering . Pravastatin treatment reduces calcific nodule formation. A, VIC cultures treated with pravastatin (100 mol/L) showed a significant reduction in the number of calcific nodules formed per cm 2 . Nodule numbers have been normalized to control conditions (no transfection and no TGF-␤1), nϭ12. B, Relative protein expression of ␣SMA in VICs after 3 days of treatment with pravastatin (100 mol/L) is shown (nϭ24). C, VICs were encapsulated in collagen gels, treated with 100 mol/L pravastatin or 5 ng/mL TGF-␤1, and released to allow gel contraction. Results are shown as reduction from original gel area with time (nϭ8). D, VICs transfected with ␣SMA-luciferase reporter plasmid were treated for 48 hours with 100 mol/L pravastatin or 5 ng/mL TGF-␤1. Relative luciferase activity is shown (nϭ18). E, Quantifiable real-time polymerase chain reaction analysis of mRNA expression of ␣SMA after cells were treated for 4 days with the indicated supplements. Expression was normalized to GAPDH (reference gene) and control (no treatment; nϭ4). *PϽ0.01 over control and between indicated groups.
the expression levels of ␣SMA, we demonstrate for the first time that this protein, a marker of myofibroblast activation, is both necessary and sufficient for initiation of calcific nodule formation in VIC cultures. A central component of stress fibers, ␣SMA appears to mediate contractile activity in these cells, which has a profound effect on initiating cell-cell aggregation that ultimately leads to calcific nodules. ␣SMA expression is repressed by treatment of VICs with pravastatin, leading to decreased contractility and nodule formation. Figure 6 provides an overview of the signaling pathways examined.
Although widely accepted as a model of valvular calcification, the processes leading to the appearance of calcific nodules in VIC cultures have not been well understood. The first study examining VIC calcific nodules described dense round nodules positive for hydroxyapatite and collagen with mostly dead cells in the core, surrounded by a ring of living cells with osteoblast-like features. 18 It was also shown that TGF-␤1, as well as oxidized lipids and BMP-2, accelerated this "spontaneous" process. 17, 18 The mechanism that initiates nodule formation remained unclear, however. To test the hypothesis that cell migrated into nodules, Jian et al treated VIC cultures with cytochalasin D as a migration inhibitor. 17 While cells were unable to move or form nodules because of a depolymerized cytoskeleton, viability was greatly reduced Figure 5 . Pravastatin does not revert preformed calcific nodules. VIC cultures were treated with or without 5 ng/mL TGF-␤1 for 4 days before treatment with 100 mol/L pravastatin. Calcium-positive nodules were counted at days 4 and 8, and the number of nodules was normalized to the day 4 untreated controls (nϭ24). *PϽ0.001 over control and between indicated groups. and calcium content of the culture was increased. Follow-up studies have focused on the role of VIC apoptosis in the calcification process. 17, 25 In apoptosis inhibition studies performed by Jian et al, no correlation was found with nodule formation and apoptosis inhibition. Rather, apotosis inhibition led to reduced calcium content but had no effect on the formation of nodules and concluded that apoptosis is not causal in nodule formation initiation. 17, 25 In our time-lapse observations was also saw no visual change in cell number (supplemental Videos I and II) and did not measure any significant change in cell dsDNA content with treatments of either TGF-␤1 or pravastatin, preliminarily indicating that proliferation is not causal in the formation of VIC calcific nodules (supplemental Figure VI) . In addition, VIC cultures may contain a subpopulation of osteoprogenitor cells that are maintained only through a limited number of population doublings and would likely not be present in cultures described herein. 28 Furthermore, from our time-lapse images, it is apparent that a large number of VICs are participating in the initial formation of nodules rather than a sub population. Although all of these studies provided valuable insight for understanding to process of calcification, none addressed the mechanism initiating nodule formation. Further, it should be noted the VIC calcific nodule formation model is inherently limited in its ability to recapitulate the exact in vivo stenotic environment, although it is a useful model for understanding basic VIC mediated calcification in a controlled and straightforward manner. Future in vivo studies will be required to understand the complete pathological situation.
In the work presented here, we sought to address this issue by first tracking nodule formation in real-time to identify the initial events that cause nodule formation without the use of cytotoxic agents that would adversely affect VIC function. Time-lapse images of VIC cultures suggested that contractility of confluent monolayers leads to the initial formation of cell aggregates that subsequently can be identified as calcific nodules.
Contractility in VICs and most fibroblastic cells is mediated through myofibroblast differentiation wherein contractile stress fibers positive for ␣SMA are formed de novo. 29 This acquisition of contractility allows fibroblastic cells to close wounds at sites of injury. In vivo, repeated mechanical loading is believed to lead to initial events triggering valvular fibrosis and calcification. 4 Additionally, increased deposition of lipids occurs, causing injury to the endothelial cell layer leading to the presence of inflammatory cells that are the sources of inflammatory cytokines such as TGF-␤1. 30 Each of these events can stimulate myofibroblast differentiation in the resident fibroblast population, and it has been shown that healthy valves consist mostly of quiescent fibroblast VICs with a small population of myofibroblastic VICs. In diseased valves, however, the VIC population shifts to be mainly activated myofibroblasts. 31 This shift toward an activated phenotype has a profound effect on ␣SMA expression and contractility of the resident VICs.
Statins, long used to inhibit HMG-CoA reductase and lower cholesterol, have recently been recognized for having beneficial effects on valvular stenosis. In the work presented here, treatment of VIC cultures with pravastatin decreased cellular contractility and nodule formation, likely a result of decreased ␣SMA expression. Previous studies also show reduced apoptosis levels, 32 alkaline phosphatase (ALP) activity, downregulation of cytokine production, 33 and reduced contractility 32 with statin treatment. Wu et al also observed mevalonate rescue of calcification in VIC cultures treated with pravastatin, but not with Manumycin, an inhibitor of farnesyl transferase, and suggest a nonprenylation pathway. 34 Monzack et al, however, showed opposite mevalonate effects and did not investigate downstream prenylation intermediates. 32 To more thoroughly investigate the mechanism of pravastatin action in these cells, we used a series of supplements and specific enzyme inhibitors to selectively analyze the isoprenylation pathways downstream of HMG-CoA reductase (supplemental Figure I and II) . Our data indicate that signaling kinases RhoA and ROCK act downstream of HMG-CoA reductase because the inhibition of either ROCK or MLCK reduces nodule formation (supplemental Figure III) in agreement with previous studies. 32 Furthermore, as shown in supplemental Figure IV, pravastatin treatment also caused a decrease in luciferase activity in VICs transfected with a pSmad-luc reporter plasmid, suggesting that statins inhibit ␣SMA expression by regulating Smad activity. These data also indicate that a link exists between RhoA activation and Smad activity, though more investigation is required to uncover the nature of this interaction. The involvement of mitogen activated kinases (MAPKs) or p38 activation are possible candidates [35] [36] [37] linking RhoA and Smad interactions.
Lastly, we were interested in investigating whether statins had the ability to reverse calcification in VIC cultures to attempt to address some of the mixed results from clinical studies. We observed that pravastatin was able to prevent additional increases in calcific nodule numbers but did not reduce or remove calcific nodules present. These data have potential ramifications in the use of statins to treat valvular fibrosis and stenosis and may help to explain some of the paradoxical clinical study results. Although the prospective studies showed no benefit of statin treatment for valvular disease, retrospective studies showed those taking statins for a long period of time for other conditions had reduced incidence of valvular fibrosis and calcification. This may be related to longer-term inhibition of VIC activation resulting in reduced fibrosis and calcification, whereas prospective study patients were treated with statins and observed for a shorter time period limiting impacts of fibrotic processes. However, mechanisms that are not present in porcine VIC cultures may exist in vivo and act to remove calcium deposits in statin-relaxed valve nodules. If so, a reduction in nodule number may be observed in human patients as a result of statin treatment.
In summary, we show for the first time that the formation of VIC calcific nodules is initiated by VIC myofibroblast activation and contractility. Moreover, statin inhibition of VIC activation is a result of reduced ␣SMA. Critical to possible clinical applications, pravastatin inhibits, but does not reverse, the formation of VIC calcific nodules. This work suggests that statins should be considered as potential therapeutics for those at risk of acquiring valvular fibrosis and stenosis and may have wider uses in the regulation of myofibroblast activity.
